Use of Patient and Disease Characteristics as Predictive Indicators of Rituximab Infusion-Related Reactions in Adult Malignant Hematology Patients at an Academic Medical Center.
BACKGROUND
Identification of predictive indicators for rituximab infusion-related reactions (R-IRRs) may allow clinicians to modify treatment plans for patients at high risk of reaction to reduce incidence. Use of predictive indicators would significantly improve the patient experience, reduce hospital resource utilization, and decrease infusion chair time.


PATIENTS AND METHODS
This retrospective, single-center, observational study evaluated 173 adult malignant hematology patients who received their first dose of rituximab inpatient between July 31, 2015 and July 31, 2018. Patients were excluded if they received prior rituximab, and/or induction chemotherapy, or were pregnant at the time of exposure. The primary outcome was the overall incidence of R-IRRs during the study period. The secondary outcomes were associations between specific patient and disease characteristics and R-IRRs.


RESULTS
Of the 173 patients evaluated, 109 met inclusion criteria and 64 were excluded. The overall incidence of R-IRRs was 31 (28.4%) of 109. The following patient and disease characteristics were significantly associated with R-IRRs on univariate analysis: higher actual body weight (P = .04), diagnosis (P = .01), lower hemoglobin (P = .02), and bone marrow involvement (P = .001). In a confirmatory stepwise regression model, higher actual body weight (P = .01) and bone marrow involvement (P = .003) were positively associated with R-IRRs.


CONCLUSION
Actual body weight and bone marrow involvement may be utilized as potential predictive indicators of R-IRRs. Further study is needed to validate these indicators and determine appropriate utilization in practice.
['Kowalski|Kaitlyn E|KE|', 'Adams|C Brooke|CB|', 'Voils|Stacy A|SA|', 'Wheeler|Sarah E|SE|']
D000046:Academic Medical Centers D000328:Adult D000368:Aged D000074322:Antineoplastic Agents, Immunological D003131:Combined Modality Therapy D064420:Drug-Related Side Effects and Adverse Reactions D005260:Female D019337:Hematologic Neoplasms D006801:Humans D007262:Infusions, Intravenous D008297:Male D008875:Middle Aged D009367:Neoplasm Staging D019233:Retreatment D000069283:Rituximab
Antibodies Antigens CD20 Cytokine release Monoclonal